MedTrace Logo

Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10

NCT05648526 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-12-13

No results posted yet for this study

Summary

The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of an adrenocorticotropic hormone (ACTH) short fragment. That is free from hormonal effects and has neuromodulatory effects. We investigate the neuroprotective effects of ACTH4-10Pro8-Gly9-Pro10 can lessen neurotoxicity against ketamine in neonatal rats by looking at BDNF expression in the cortex and hippocampus tissue as well as BDNF blood levels.

Conditions

  • Ketamine-Induced Neurotoxicity

Interventions

DRUG

ACTH4-10Pro8-Gly9-Pro10

ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis

DRUG

Ketamine

negative-positive control (ketamine 40 mg/kg BW subcutaneously)

Sponsors & Collaborators

  • Universitas Sumatera Utara

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
7 Days
Max Age
7 Days
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2021-09-30
Completion
2021-10-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05648526 on ClinicalTrials.gov